Trials / Available
AvailableNCT04745637
Managed Access Programs for INC424, Ruxolitinib
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib
Detailed description
CINC424A2405 - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424A2405 to provide access to Ruxolitinib for patients with Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) CINC424A2001M - No longer available - Ruxolitinib Managed Access Program (MAP) for patients diagnosed with severe/very severe COVID-19 illness CINC424B2002I - No longer available- Managed Access Program (MAP) Cohort Treatment Plan CINC424B2002I to provide access to Ruxolitinib for patients with Polycythemia Vera (PV) CINC424C2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CINC424C2001M to provide access to ruxolitinib for steroid refractory acute and chronic Graft versus Host Disease (SR aGVHD and SR cGHVD).
Conditions
- Primary Myelofibrosis (PMF)
- Post Polycythemia Myelofibrosis (PPV MF)
- Thrombocythemia Myelofibrosis (PET-MF)
- Severe/Very Severe COVID-19 Illness
- Polycythemia Vera (PV)
- Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD)
- Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Patients receive Ruxolitinib |
Timeline
- First posted
- 2021-02-09
- Last updated
- 2025-11-18
Source: ClinicalTrials.gov record NCT04745637. Inclusion in this directory is not an endorsement.